Business
Issue of equity in respect of options exercise
Issue of equity in respect of options exercise.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 0131T Allergy Therapeutics PLC 23 March 2016 \n\n \n \n \n \n \n23 March 2016\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nIssue of equity in respect of the exercise of options\n \n \nAllergy Therapeutics announces the issue and allotment of 2,305,089 new ordinary shares of 0.1p each in the capital of the Company (\"Ordinary Shares\") pursuant to the exercise of 2,305,089 share options by certain employees.\n \nApplication has been made to the London Stock Exchange for admission to trading of the new Ordinary Shares on AIM (\"Admission\"). It is expected that Admission will take place and that dealings in the new Ordinary Shares on AIM will commence at 8:00 a.m. on 29 March 2016. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new Ordinary Shares.\n \nAllergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 589,158,508 Ordinary Shares with voting rights attached. The Company has no Ordinary Shares in Treasury; therefore the total number of voting rights in Allergy Therapeutics is 589,158,508. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\n \nENDS\nFor further information please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton\[email protected]\n \n\n\n \nNote to editors:\n \nAbout Allergy Therapeutics\nAllergy Therapeutics is an international specialty pharmaceutical company focussed on ...